HC Wainwright Reiterates Buy Rating for AEON Biopharma (NASDAQ:AEON)

AEON Biopharma (NASDAQ:AEON)‘s stock had its “buy” rating restated by HC Wainwright in a research note issued on Wednesday, Benzinga reports. They currently have a $18.00 price target on the stock. HC Wainwright’s price objective indicates a potential upside of 175.23% from the stock’s current price. HC Wainwright also issued estimates for AEON Biopharma’s Q1 2025 earnings at ($0.29) EPS, Q2 2025 earnings at ($0.31) EPS, Q3 2025 earnings at ($0.32) EPS and Q4 2025 earnings at ($0.24) EPS.

AEON Biopharma Stock Performance

NASDAQ AEON opened at $6.54 on Wednesday. AEON Biopharma has a one year low of $3.37 and a one year high of $17.17. The company’s 50 day moving average price is $10.64 and its 200 day moving average price is $7.78.

AEON Biopharma (NASDAQ:AEON) last posted its quarterly earnings results on Friday, March 29th. The company reported ($0.71) EPS for the quarter. Equities analysts anticipate that AEON Biopharma will post -1.54 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the business. Atalaya Capital Management LP acquired a new stake in AEON Biopharma in the third quarter valued at approximately $19,827,000. Formidable Asset Management LLC acquired a new stake in AEON Biopharma in the third quarter valued at approximately $360,000. Vanguard Group Inc. grew its position in AEON Biopharma by 8.3% in the fourth quarter. Vanguard Group Inc. now owns 209,785 shares of the company’s stock valued at $1,510,000 after acquiring an additional 16,091 shares in the last quarter. Finally, Northern Trust Corp grew its position in AEON Biopharma by 53.4% in the fourth quarter. Northern Trust Corp now owns 49,819 shares of the company’s stock valued at $359,000 after acquiring an additional 17,341 shares in the last quarter. Hedge funds and other institutional investors own 22.78% of the company’s stock.

AEON Biopharma Company Profile

AEON Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed a Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine.